Heat Biologics, Inc. (NASDAQ:HTBX) has been assigned an average broker rating score of 1.00 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy recommendation.

Brokerages have set a 12 month consensus price objective of $8.42 for the company and are forecasting that the company will post ($0.09) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Heat Biologics an industry rank of 104 out of 265 based on the ratings given to related companies.

Separately, Griffin Securities began coverage on Heat Biologics in a research note on Tuesday, September 12th. They issued a “buy” rating and a $2.25 target price for the company.

Shares of Heat Biologics (NASDAQ:HTBX) traded down $0.03 during mid-day trading on Tuesday, reaching $0.43. The company had a trading volume of 423,000 shares, compared to its average volume of 605,148. Heat Biologics has a one year low of $0.41 and a one year high of $1.44.

Heat Biologics (NASDAQ:HTBX) last issued its earnings results on Monday, November 13th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.03. The company had revenue of $0.47 million during the quarter, compared to analyst estimates of $0.50 million. Heat Biologics had a negative return on equity of 149.69% and a negative net margin of 1,184.92%. analysts forecast that Heat Biologics will post -0.38 earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Heat Biologics stock. KCG Holdings Inc. raised its stake in shares of Heat Biologics, Inc. (NASDAQ:HTBX) by 35.3% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 175,769 shares of the biopharmaceutical company’s stock after buying an additional 45,831 shares during the period. KCG Holdings Inc. owned about 0.52% of Heat Biologics worth $156,000 at the end of the most recent quarter. Institutional investors and hedge funds own 8.37% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/05/zacks-analysts-set-8-42-price-target-for-heat-biologics-inc-htbx.html.

About Heat Biologics

Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).

Get a free copy of the Zacks research report on Heat Biologics (HTBX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Heat Biologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.